AGNPF
Grey Matters Health Inc.
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Strong sell
-75/100
Last price
0.29
▲ 0.04 (14.40%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.25
Day high
0.28
Day low
0.28
Volume
2.50K
Market cap
$2.76M
P/E (TTM)
—
52W range
0.22 – 0.64
Trailing performance
Returnvs SPY
1W
+0.99%
-0.7%
1M
-31.73%
-33.0%
3M
-10.72%
-13.9%
6M
-28.26%
-43.0%
YTD
-42.75%
-56.5%
1Y
-48.14%
-63.7%
3Y
-73.72%
-155.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AGNPF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
488.99K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 9, 26 | Moreau (Christopher) Director of Issuer |
BUY | 87.50K | $25.38K | Indirect |
| Aug 26, 26 | Moreau (Christopher) Director of Issuer |
— | 100.00K | — | Indirect |
| Aug 17, 26 | Attariwala (Rajpaul) Director of Issuer |
— | 45.00K | — | Direct |
| Aug 17, 26 | Bloomfield (Harry J F) Director of Issuer |
— | 90.00K | — | Direct |
| Aug 17, 26 | Bryan (Christopher Scott) Senior Officer of Issuer |
— | 135.00K | — | Indirect |
| Aug 17, 26 | Gutman (Howard) Director of Issuer |
— | 45.00K | — | Direct |
| Aug 17, 26 | Kinley (James F CA) Senior Officer of Issuer |
— | 170.00K | — | Indirect |
| Aug 17, 26 | Moreau (Christopher) Director of Issuer |
— | 220.00K | — | Indirect |
| Aug 17, 26 | Moreau, Paul Joseph Senior Officer of Issuer |
— | 135.00K | — | Indirect |
| Aug 17, 26 | Williams, Mark Stephen Director of Issuer |
— | 45.00K | — | Direct |
| Jul 1, 26 | Moreau, Paul Joseph Senior Officer of Issuer |
— | 0 | — | Direct |
| Jul 1, 26 | Moreau, Paul Joseph Senior Officer of Issuer |
— | 0 | — | Indirect |
| Jun 17, 26 | Bloomfield (Harry J F) Director of Issuer |
BUY | 87.50K | $24.85K | Direct |
| Jun 17, 26 | Gutman (Howard) Director of Issuer |
BUY | 100.00K | $28.40K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Attariwala (Rajpaul) |
Director of Issuer | 130.94K | Exercise of rights |
Bloomfield (Harry J F) |
Director of Issuer | 215.83K | Exercise of rights |
Bryan (Christopher Scott) |
Senior Officer of Issuer | — | Exercise of rights |
Gutman (Howard) |
Director of Issuer | 161.50K | Exercise of rights |
Kinley (James F CA) |
Senior Officer of Issuer | — | Exercise of rights |
Moreau (Christopher) |
Director of Issuer | — | Acquisition or disposition under a prospectus exemption |
Moreau, Paul Joseph |
Senior Officer of Issuer | — | Exercise of rights |
Williams, Mark Stephen |
Director of Issuer | 142.48K | Exercise of rights |
Fundamentals
Market cap$2.76M
Enterprise value$3.92M
Revenue (TTM)—
Gross profit—
EBITDA$-1.77M
Net income$-2.18M
EPS (TTM)$-0.36
Free cash flow$-1.38M
Total cash$41.66K
Total debt$778.79K
Book value / share$0.14
Shares outstanding9.64M
Float7.21M
Short % of float—
Dividend yield0.00%
Beta (5Y)1.09
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book1.98
EV / revenue—
EV / EBITDA-2.22
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-124.73%
Return on assets-23.51%
Debt / equity44.44
Current ratio0.13
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $80.57K | $651.16K | $1.10M | $2.29M | -87.6% |
| Selling, general & admin | $1.64M | $1.76M | $4.15M | $3.73M | -7.0% |
| Total operating expense | $1.72M | $2.41M | $5.24M | $6.02M | -28.8% |
| Operating income | -$1.72M | -$2.41M | -$5.24M | -$6.02M | +28.8% |
| Net interest income | $739 | $1.37K | $2.10K | $2.08K | -46.0% |
| Pre-tax income | -$1.72M | -$502.98K | -$6.78M | -$6.05M | -241.4% |
| Net income | -$1.72M | -$502.98K | -$6.78M | -$6.05M | -241.4% |
| Net income to common | -$1.72M | -$502.98K | -$6.78M | -$6.05M | -241.4% |
| Basic EPS | -0.60 | -0.30 | -4.50 | -8.70 | -100.0% |
| Diluted EPS | -0.60 | -0.30 | -4.50 | -8.70 | -100.0% |
| EBIT | -$1.72M | -$2.41M | -$5.24M | -$6.02M | +28.8% |
| EBITDA | -$1.66M | -$2.39M | -$5.19M | -$5.99M | +30.3% |
| Basic shares | 2.95M | 2.00M | 1.51M | 695.25K | +47.1% |
| Diluted shares | 2.95M | 2.00M | 1.51M | 695.25K | +47.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $176.50K | $596.20K | $125.08K | $1.41M | -70.4% |
| Cash & short-term investments | $176.50K | $596.20K | $125.08K | $1.41M | -70.4% |
| Total current assets | $554.47K | $738.76K | $339.83K | $2.83M | -24.9% |
| Goodwill & intangibles | $4.29M | $3.18M | $3.80M | $5.26M | +35.2% |
| Total assets | $4.88M | $3.94M | $4.19M | $8.14M | +23.7% |
| Total current liabilities | $2.18M | $1.78M | $2.72M | $2.52M | +22.9% |
| Total liabilities | $2.18M | $1.78M | $2.72M | $2.52M | +22.9% |
| Retained earnings | -$30.56M | -$30.76M | -$30.79M | -$25.19M | +0.6% |
| Shareholder equity | $2.70M | $2.17M | $1.47M | $5.62M | +24.3% |
| Working capital | -$1.63M | -$1.04M | -$2.38M | $311.00K | -57.0% |
| Net tangible assets | -$1.60M | -$1.01M | -$2.32M | $368.50K | -58.6% |
| Shares issued | 3.43M | 2.73M | 1.58M | 1.13M | +25.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$1.72M | -$502.98K | -$6.78M | -$6.05M | -241.4% |
| Depreciation & amortisation | $54.69K | $26.56K | $50.40K | $34.94K | +105.9% |
| Stock-based compensation | $196.12K | $286.66K | $1.26M | $530.84K | -31.6% |
| Change in working capital | $257.13K | -$616.20K | $1.27M | $2.58M | +141.7% |
| Operating cash flow | -$1.16M | -$2.71M | -$2.55M | -$2.91M | +57.3% |
| Capital expenditure | -$24.97K | -$84.03K | -$59.50K | -$144.61K | +70.3% |
| Investing cash flow | $150.03K | $2.28M | -$59.50K | -$144.61K | -93.4% |
| Financing cash flow | $587.31K | $901.09K | $1.33M | $2.06M | -34.8% |
| Free cash flow | -$1.18M | -$2.79M | -$2.61M | -$3.06M | +57.7% |
| End cash position | $176.50K | $596.20K | $125.08K | $1.41M | -70.4% |
| Line item | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $22.00K | $1.52K | $26.45K | $12.06K | $26.20K | — | +1,350.0% |
| Selling, general & admin | $539.75K | $498.11K | $570.75K | $368.67K | $557.01K | — | +8.4% |
| Total operating expense | $561.75K | $499.63K | $597.20K | $380.73K | $583.21K | — | +12.4% |
| Operating income | -$561.75K | -$499.63K | -$597.20K | -$380.73K | -$583.21K | — | -12.4% |
| Net interest income | -$12.04K | $104 | $196 | $233 | -$14 | — | -11,676.0% |
| Pre-tax income | -$702.03K | -$499.52K | -$597.01K | -$380.50K | -$583.23K | — | -40.5% |
| Net income | -$702.03K | -$499.52K | -$597.01K | -$380.50K | -$583.23K | — | -40.5% |
| Net income to common | -$702.03K | -$499.52K | -$597.01K | -$380.50K | -$583.23K | — | -40.5% |
| Basic EPS | -0.13 | -0.11 | -0.20 | — | -0.20 | -0.14 | -18.2% |
| Diluted EPS | -0.13 | -0.11 | -0.20 | — | -0.20 | -0.14 | -18.2% |
| EBIT | -$689.97K | -$499.63K | -$597.20K | -$380.73K | -$583.21K | — | -38.1% |
| EBITDA | -$635.78K | -$464.34K | -$562.75K | -$346.25K | -$574.55K | — | -36.9% |
| Basic shares | 5.42M | 4.69M | 3.48M | — | 2.90M | 2.73M | +15.7% |
| Diluted shares | 5.42M | 4.69M | 3.48M | — | 2.90M | 2.73M | +15.7% |
| Line item | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $41.66K | $195.35K | $210.03K | $176.50K | $88.18K | — | -78.7% |
| Cash & short-term investments | $41.66K | $195.35K | $210.03K | $176.50K | $88.18K | — | -78.7% |
| Accounts receivable | $17.45K | $26.65K | $15.85K | — | $14.94K | $19.55K | -34.5% |
| Total current assets | $359.19K | $631.18K | $613.56K | $554.47K | $233.88K | — | -43.1% |
| Property, plant & equipment | $747.97K | — | — | — | — | — | — |
| Goodwill & intangibles | $4.14M | $4.29M | $4.29M | $4.29M | $4.62M | — | -3.5% |
| Total assets | $5.28M | $4.95M | $4.93M | $4.88M | $4.88M | — | +6.6% |
| Total current liabilities | $2.80M | $2.49M | $2.44M | $2.18M | $2.87M | — | +12.2% |
| Total debt | $778.79K | — | — | — | — | — | — |
| Total liabilities | $3.52M | $2.49M | $2.44M | $2.18M | $3.14M | — | +41.3% |
| Retained earnings | -$31.89M | -$31.19M | -$30.76M | -$30.56M | -$30.45M | — | -2.3% |
| Shareholder equity | $1.75M | $2.45M | $2.49M | $2.70M | $1.74M | — | -28.6% |
| Working capital | -$2.44M | -$1.86M | -$1.83M | -$1.63M | -$2.64M | — | -31.0% |
| Net tangible assets | -$2.39M | -$1.83M | -$1.80M | -$1.60M | -$2.88M | — | -30.2% |
| Shares issued | 5.42M | 5.42M | 3.98M | 3.43M | 3.43M | — | 0.0% |
| Line item | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$702.03K | -$499.43K | -$597.01K | -$380.50K | -$583.23K | -40.6% |
| Depreciation & amortisation | $54.19K | $35.29K | $34.45K | $34.48K | $8.66K | +53.6% |
| Stock-based compensation | $0 | $0 | $455 | -$14.18K | $210.30K | — |
| Change in working capital | $353.02K | $17.07K | $190.46K | -$141.33K | $200.47K | +1,968.4% |
| Operating cash flow | -$145.01K | -$465.98K | -$356.91K | -$489.06K | -$174.52K | +68.9% |
| Capital expenditure | -$10.05K | — | — | -$9.75K | — | — |
| Investing cash flow | -$10.05K | — | — | -$9.75K | $175.00K | — |
| Financing cash flow | $0 | $470.00K | $387.00K | $587.10K | $0 | -100.0% |
| Free cash flow | -$155.06K | -$480.22K | -$356.91K | -$498.80K | -$174.52K | +67.7% |
| End cash position | $41.66K | $195.35K | $210.03K | $176.50K | $88.18K | -78.7% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders5.48%
Held by institutions14.40%
Institutions holding1
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.29
-1.80% from price
SMA 20
0.33
-11.97% from price
SMA 50
0.33
-12.10% from price
SMA 100
0.32
-10.26% from price
SMA 200
0.34
-16.03% from price
EMA 12
0.30
-3.89% from price
EMA 26
0.32
-9.73% from price
EMA 50
0.32
-11.29% from price
RSI (14)
44.1
Neutral
MACD (12,26,9)
-0.02
Hist -0.01
ATR (14)
0.03
10.22% of price
Realised vol 30D
152.2%
Annualised
Bollinger upper
0.41
20, 2σ
Bollinger lower
0.24
20, 2σ
50 / 200 cross
Death
0.33 vs 0.34
Trend bias
Below 200
-16.03%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.22
Less volatile than market
Correlation to SPY
-0.02
Largely independent
Realised vol 30D
152.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-64.1%
Peak to trough
Max drawdown 5Y
-98.8%
Peak to trough
ATR 14
0.03
10.22% of price
Beta (reported)
1.09
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateOct 17, 2018
Last split1:10
Split dateApr 21, 2026
SEC filings
Additional Forms
D · 2026-06-26
Additional Forms
D/A · 2025-12-09
Additional Forms
D · 2025-12-01
Additional Forms
D · 2024-04-10
Registration Withdrawal Request
RW · 2022-12-21
Offering Registrations
F-1/A · 2022-06-03
Offering Registrations
F-1/A · 2022-05-09
Offering Registrations
F-1/A · 2022-04-25
Headlines
Grey Matters closes $1.12M funding for Alzheimer's research
Proactive · 14d ago
Grey Matters Announces the Closing of its Equity and Convertible Debenture Private Placement totalling CAD $1.12 Million
GlobeNewswire · 14d ago
Grey Matters Announces an Increase to its Equity and Convertible Debenture Private Placement to CAD $1.1 Million
GlobeNewswire · 21d ago
Grey Matters Closes First Tranche of $600,000 of its Equity and Convertible Debenture Private Placement
GlobeNewswire · 27d ago
Grey Matters Health secures key Florida licence – ICYMI
Proactive · 46d ago
Grey Matters Achieves Final Major Milestone; Receives Radioactive Materials License from State of Florida for its Flagship NovaScan Neuroimaging Clinics™ Location
GlobeNewswire · 48d ago
Grey Matters Health secures Florida radioactive materials license for flagship neuroimaging clinic
Proactive · 48d ago
Grey Matters Announces CAD $800K of Private Placement Equity Financing and Convertible Debentures
GlobeNewswire · 48d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.